Can GLP-1 Drugs Help With Addiction and Recovery?

Yes, GLP-1 drugs may help with addiction by reducing cravings, quieting the brain’s reward signals, and making it easier to resist the pull of substances. Originally developed to treat diabetes and obesity, medications like Ozempic and Wegovy are now at the centre of some of the most promising addiction research in years. This guide explains what GLP-1s are, how they work in the brain, and what the latest findings could mean for people in recovery.

Key Facts About GLP-1 Drugs and Addiction

• GLP-1 drugs were originally approved to treat type 2 diabetes and obesity
• They work partly by targeting the brain’s reward system, the same system involved in addiction
• Early research suggests they may reduce cravings for alcohol, opioids, nicotine, and cocaine
• One study found people taking GLP-1s had a 40 per cent lower rate of opioid overdose
• They are not yet approved as addiction treatments and most use is currently off-label
• Larger clinical trials are underway, with results expected in the near future

Call 0203 955 7700 Today For Confidential Addiction Support

What Are GLP-1 Drugs and How Do They Work?

GLP-1 drugs are a class of medication that mimic a hormone your body naturally produces after eating, slowing digestion, boosting insulin, and reducing appetite. They are best known under brand names like Ozempic, Wegovy, and Mounjaro, and have been widely prescribed for weight loss and blood sugar control over the past decade. What makes them particularly interesting for addiction research is that their effects do not stop at the gut.

GLP-1 receptors are found throughout the brain, including in the areas that regulate dopamine, motivation, and reward. Dopamine is the chemical messenger at the core of addiction, driving the urge to seek out substances again and again. By influencing how dopamine behaves in these regions, GLP-1 drugs appear to reduce the intensity of cravings across a surprisingly wide range of substances and behaviours.

How Could GLP-1 Drugs Help People Struggling With Addiction?

GLP-1 drugs could help people struggling with addiction by reducing cravings and compulsive behaviours in the same way they suppress appetite, targeting the brain’s reward system rather than just the body’s hunger signals.

Clinicians first began noticing something unexpected among patients already taking GLP-1 medications for weight loss. Many reported that they had stopped smoking, cut back on alcohol, or simply lost interest in substances they had long struggled to resist. These reports were anecdotal at first, but they were consistent enough to prompt researchers to take a much closer look.

The findings have been encouraging. In one study, people with opioid or alcohol use disorder who were taking GLP-1 medications had a 40 per cent lower rate of opioid overdose and a 50 per cent lower rate of alcohol intoxication compared to those not on the drugs. These are significant figures, though researchers are careful to point out that larger, longer trials are still needed before any firm conclusions can be drawn.

Call 0203 955 7700 Today For Confidential Addiction Support

Which Addictions Could GLP-1 Drugs Potentially Treat?

GLP-1 drugs could potentially treat a range of addictions including alcohol, opioids such as heroin, fentanyl and oxycodone, nicotine, and possibly other compulsive behaviours driven by the brain’s reward system. Research so far points to a much broader application than most addiction medications ever achieve.

Studies have shown that GLP-1 receptor agonists may reduce cravings and consumption across multiple substances, which is unusual because most existing addiction medications are designed to target one specific substance or receptor. The fact that these drugs appear to work across different addiction types suggests they are acting on something more fundamental in the reward pathway rather than a substance-specific mechanism.

Alcohol use disorder is currently the most researched application outside of weight loss, with several trials showing meaningful reductions in drinking frequency and quantity among participants taking GLP-1 medications. The evidence for opioid addiction is earlier stage but encouraging, and nicotine dependence is another area where anecdotal reports from patients have prompted more formal investigation.

It is worth being clear that none of these applications are licensed in the UK yet, and GLP-1 drugs are not currently prescribed for addiction treatment outside of clinical trials. However the breadth of the potential applications is what makes this an area of genuine excitement in addiction medicine, and the pace of research is accelerating.

Are GLP-1 Drugs Available as an Addiction Treatment in the UK?

Not yet as a licensed treatment specifically for addiction. In the UK, GLP-1 drugs are currently approved for type 2 diabetes and obesity only. Any use for addiction is off-label, meaning a doctor can prescribe them for this purpose, but it sits outside the drug’s official licensed indication. Routine NHS prescribing for addiction treatment is not currently available on this basis.

That said, the research landscape is moving quickly and several well-designed clinical trials are expected to report results in the coming months, particularly around alcohol use disorder. These could accelerate the path towards broader approval and NHS access. If you are in recovery and want to explore whether GLP-1 medications could be relevant to your situation, speaking to your GP or an addiction specialist is the best starting point.

What Are the Side Effects to Know About GLP-1 Drugs?

The side effects and limitations of GLP-1 drugs include nausea, vomiting, fatigue, and digestive discomfort, and there are significant gaps in the evidence that mean they are not yet a reliable standalone treatment for addiction. GLP-1 drugs are not a straightforward solution, and it is important to have realistic expectations going in.

Nausea is the most commonly reported side effect and tends to be most pronounced in the early weeks of treatment as the body adjusts to the medication. For most people it eases over time, but for some it is significant enough to lead to stopping the medication altogether. Vomiting, diarrhoea, constipation, and reduced appetite are also frequently reported, and in some cases the appetite suppression is severe enough to cause nutritional concerns.

More serious but less common side effects include pancreatitis, gallbladder problems, and in animal studies an association with thyroid tumours, though the relevance of the latter to humans is still being investigated. People with a personal or family history of certain thyroid conditions are generally advised not to take GLP-1 medications.

From a limitations standpoint, the evidence base for using these drugs specifically for addiction is still early stage. Most studies have been small, short term, or conducted in animal models rather than large human trials. There is also the question of what happens when the medication is stopped, whether cravings and compulsive behaviours return, which remains unanswered. Cost and access are additional barriers, as GLP-1 medications are expensive and not currently available on the NHS for addiction treatment.

Could GLP-1 Drugs Change the Way We Treat Addiction in the Future?

Possibly, and the level of interest from researchers is genuine and growing. What sets GLP-1s apart from most existing treatments is the possibility that they could work across multiple substance use disorders at the same time, something no approved medication currently does. Early animal studies and small human trials have both shown consistent, encouraging results across a range of substances.

The National Institute on Drug Abuse has described early data in this area as very exciting, while also acknowledging that pharmaceutical investment in addiction treatment has historically fallen well short of the scale of the problem. GLP-1s remain a promising area of research rather than a finished solution for now. But for people in recovery and those who support them, the direction of travel is a genuinely hopeful one.

While We Wait, What Else Can Help With Addiction Recovery?

GLP-1 research is promising, but effective addiction treatment does not have to wait for new medications to be approved. Proven options are available right now, and for many people a combination of approaches works far better than any single treatment on its own. If you or someone you know is struggling, the most important step is simply reaching out for support.

Treatments that have a strong track record include residential rehab, cognitive behavioural therapy, and medication-assisted treatment for opioid and alcohol dependence. Peer support groups such as Alcoholics Anonymous and Narcotics Anonymous have also helped millions of people maintain long-term sobriety, and they are free to access. None of these require waiting for clinical trials to conclude.

At Help4Addiction, we can help you find the right treatment for your situation, whether that is a rehab programme, a local support group, or simply a conversation about where to start. Recovery is possible today, with the tools and support that already exist. Get in touch with our team for free, confidential advice on the options available to you.